#USA #Calgary #Innocan Pharma #LPT-CBD #CBD

Innocan Pharma's 2024 Annual Research and Development Update

Innocan Pharma Corporation, a pioneering company in pharmaceutical technologies, has recently laid out its annual update on research and development for the year 2024. The report highlights substantial milestones achieved in advancing its innovative drug delivery platforms, especially focusing on liposome-cannabidiol technology (LPT-CBD), which aims to enhance pain management solutions for both human and veterinary applications.

Major Achievements in 2024

1. Breakthrough in Preclinical Studies
This year marked a significant achievement wherein preclinical studies of LPT-CBD demonstrated impressive results, including high bioavailability of CBD, long-lasting pain relief, and improvements in overall well-being across various animal models. Due to these compelling data, Innocan received formal agreement from the U.S. Food and Drug Administration (FDA) on their preclinical and Phase 1 clinical development plan for advancing LPT-CBD as a chronic pain treatment for humans. Additionally, the FDA acknowledged the innovative platform's development under the 505(b)(2) regulatory pathway, offering Innocan an expedited route for patent utilization and commercialization.

2. Recognition from Veterinary Authorities
In a commendable stride forward for veterinary medicine, the FDA's Center for Veterinary Medicine (CVM) recognized Innocan's innovations by granting a fee waiver for 2024 and an Investigational New Animal Drug (INAD) designation for LPT-CBD. This has enabled the company to streamline communication and data exchange with the CVM to facilitate developing LPT-CBD as a new veterinary product.

3. Regulatory Milestones
CEO Iris Bincovich expressed her pride in surpassing FDA-related goals and achieving milestones well ahead of schedule. The 505(b)(2) regulatory pathway significantly accelerates the development timeline and reduces costs, facilitating modifications while meeting rigorous safety standards. This strategic route is anticipated to address untapped medical needs in chronic pain therapy.

The Path to Human Clinical Trials

In an ongoing pursuit of innovation, Innocan reported various significant events in 2024:

• - Pre-IND Meeting: Submitting a letter of application for a Pre-IND meeting on April 22, 2024, underscored the company’s first stride towards FDA approval for LPT-CBD in humans.
• - Successful Animal Testing: Demonstrated promising results in treating laboratory animals. For instance, Miri, a female donkey that underwent amputation due to an inflammatory condition, exhibited immediate pain relief and mobility restoration following a LPT-CBD injection.
• - Positive FDA Responses: The FDA's positive feedback following Innocan's pre-IND Type B meeting greatly encourages its roadmap toward clinical trials for LPT-CBD. At this meeting, Innocan presented its preclinical results and plans for clinical development, leading to crucial potential approval for testing on human subjects.

Noteworthy Studies and Applications

Innovative studies, especially using LPT-CBD, indicate potential therapeutic opportunities beyond pain management:

• - A pharmacokinetic study conducted on rabbits led to prolonged exposure and retention of CBD following single subcutaneous injections.
• - LPT-CBD was found effectively to penetrate the blood-brain barrier, raising possibilities for neurological disorder treatments.
• - On the veterinary side, consistent results from dogs suffering osteoarthritis demonstrated noticeable pain relief and enhanced mobility after LPT-CBD administration, indicating prolonged beneficial effects for animals.

The Future of Innocan Pharma

Innocan Pharma is set to pave the way towards innovative, non-opioid solutions in pain management both for humans and animals. The company's consistent advancements in the regulatory landscape and notable support from industry experts, including Dr. William K. Schmidt, emphasize its commitment towards achieving FDA approvals effectively while exploring diverse therapeutic pathways.

Innocan stands as a testament to the future of pharmaceutical innovations, ready to bring transformative solutions to chronic pain management, reliant not just on scientific advancements but also on regulatory cooperation. This trajectory sets Innocan Pharma on an exciting journey as it gears up for faster approvals that can lead to improved quality of life for many.

For more updates about Innocan Pharma and its endeavors in the pharmaceutical domain, visit Innocan Pharma.